Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1

Interventions

Magnetic Resonance Spectroscopy 86pembrolizumab 76Specimen Handling 75enzalutamide 55Radiosurgery 55Radiotherapy 51Docetaxel 50Androgen Antagonists 47Gemcitabine 42Nivolumab 39darolutamide 37Prednisone 35enfortumab vedotin 32Abiraterone Acetate 31Cisplatin 30Biopsy 30Carboplatin 29cabozantinib 28Standard of Care 28apalutamide 27Pluvicto 26abiraterone 25Blood Specimen Collection 25Radiation 23Leuprolide 23Ipilimumab 22X-Rays 18relugolix 17Triptorelin Pamoate 17Surveys and Questionnaires 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Vancomycin × Genitourinary × Clear all
NCT06126731 2025-11-24

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting
39 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡